Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia

Table 2 Multivariate analysis of III-IV aGVHD and cGVHD

Outcome	Variate	HR(95%CI)	P Value
III-IV aGVHD
	Patient age groups	32.51(3.68–287.20)	0.002
	Conditioning regimen	4.06(0.68–24.05)	0.123
	Graft source	0.25(0.03–2.13)	0.207
	Donor types	1.26(0.20–7.94)	0.805
cGVHD
	Donor gender	4.52(0.74–27.65)	0.102
	Graft source	0.27(0.04–1.80)	0.177
	Second HSCT	4.42(0.32–60.31)	0.265

Abbreviations: aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; HR, hazard ratio

ISSN: 1479-5876